Perjeta 1 Vial 420 mg/14 ml
1 Vial — 420 mg/14 ml
Perjeta (pertuzumab) is a monoclonal antibody used to treat HER2-positive metastatic breast cancer in combination with other medications. It works by targeting and blocking HER2, a protein found on some cancer cells.
- Turkish packaging
- Active ingredient: Pertuzumab
Perjeta is a targeted therapy for the treatment of HER2-positive metastatic breast cancer. Perjeta is a monoclonal antibody medication that works by binding to the HER2 protein on the surface of cancer cells. When attached to the protein, Perjeta blocks the HER2 protein from sending signals that promote tumor growth and allows chemotherapy to enter the cells more efficiently. Perjeta is used in combination with Herceptin and chemotherapy to treat HER2-positive metastatic breast cancer. The combination of Perjeta and Herceptin is the first targeted therapy that has been shown to extend overall survival in people with HER2-positive metastatic breast cancer. Perjeta is a fast-acting medication that is administered intravenously by a healthcare provider.
Common side effects of Perjeta include fatigue, nausea, diarrhea, vomiting, and a decrease in white blood cells.